Norton Rose Fulbright Canada LLP
Related services and key industries
Daniel Weiss is corporate and commercial lawyer in our corporate, M&A and securities group and is part of the life sciences and healthcare team.
Daniel acts for clients in connection with hostile and friendly M&A transactions as well as public offerings and private placements. He regularly advises on public disclosure, corporate governance. and other securities law matters.
Daniel also advises clients on Health Canada regulatory matters, including licencing, product compliance and advertising and promotion matters for clients in the cannabis, pharmaceutical and medical devices sectors. His experience includes advising on Health Canada regulatory matters in connection with M&A transactions in the cannabis and pharmaceutical sectors.
Daniel joined us as a summer student in 2017 and returned as an articling student the following year. During his articles, he completed a secondment in the legal department of Scotiabank where he gained valuable experience working on a variety of commercial and regulatory matters. Before joining us, Daniel worked in the compliance department of a major Canadian financial institution.
Capital Markets Modernization Taskforce recommendations, Part 5: financial firms and capital markets plumbing
Publication | March 23, 2021
Publication | March 18, 2021
Publication | March 10, 2021
Capital Markets Modernization Taskforce recommendations, Part 2: modernizing capital raising requirements
Publication | March 3, 2021